Pirfenidone Tablet, Coated
Product Images NDC 62332-479

8 FDA label images from Alembic Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 62332-479). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pirfenidone (Pirfenidone Structure)

Pirfenidone (Pirfenidone Structure)
Chemical structure of Pirfenidone, showing its molecular arrangement including benzene rings and functional groups.*
FDA Label Image

Figure 1 (Pirfenidone Figure1)

Figure 1 (Pirfenidone Figure1)
A cumulative distribution curve showing the percent of patients versus absolute change in percent predicted forced vital capacity (%FVC) from baseline to week 52. Two groups are compared: Pirfenidone (n=278) represented by a solid line and placebo (n=277) by a dotted line. The x-axis ranges from -30% to +10% change in %FVC, with worsening indicated by decreases and no decline by increases. Specific percentile points are marked, such as 32% and 17% worsening at around -10%, and 90% and 77% with no decline near 0% change.*
FDA Label Image

Figure 2 (Pirfenidone Figure2)

Figure 2 (Pirfenidone Figure2)
A line graph comparing the mean change in Forced Vital Capacity (FVC) in mL over 52 weeks between two groups: Pirfenidone (n=278) and Placebo (n=277). The graph shows a decreasing trend for both groups, with the placebo group experiencing a greater decline in FVC over time compared to the Pirfenidone group.*
FDA Label Image

Figure 3 (Pirfenidone Figure3)

Figure 3 (Pirfenidone Figure3)
A Kaplan-Meier survival curve plot showing the percentage of patients alive over time in weeks. It compares Pirfenidone (solid line) with placebo (dotted line), including the number of patients at risk at various time points and a hazard ratio (HR) with 95% confidence interval (CI) indicated on the graph.*
FDA Label Image

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)

Pirfenidone-pi-table1 (Pirfenidone Pi Table 1)
A dosing schedule table for Pirfenidone Tablets 267 mg showing the number of pills taken in the morning, afternoon, and evening across different weeks. It details pill counts for days 1 to 7, days 8 to 14, and from day 15 onward, with total daily pills increasing from 3 to 9.*
FDA Label Image

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)

Pirfenidone-pi-table-2 (Pirfenidone Pi Table 2)
A dosing schedule table for Pirfenidone Tablets 801 mg showing the number of tablets to be taken at three daily times: 1 tablet each at morning (breakfast), afternoon (lunch), and evening (dinner), totaling 3 pills each day starting from day 15 onward.*
FDA Label Image

500 Tablets (Pirfenidone 267 mg 500tablets)

500 Tablets (Pirfenidone 267 mg 500tablets)
Label for Pirfenidone Tablets 267 mg, oral coated tablets, manufactured by Alembic Pharmaceuticals Limited. The packaging indicates a quantity of 500 tablets and includes storage instructions, a barcode, and the NDC number 62332-479-71. The label shows the Alembic logo and states the product is Rx only with a caution to keep out of reach of children.*
FDA Label Image

500 Tablets (Pirfenidone 801 mg 500tablats)

500 Tablets (Pirfenidone 801 mg 500tablats)
Pirfenidone Tablets 801 mg coated oral tablets packaging label. The label includes dosing information, storage instructions at 25°C with permitted excursions, and manufacturer details of Alembic Pharmaceuticals Limited (India) and Alembic Pharmaceuticals, Inc. (USA). The package contains 500 tablets and is Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.